Abstract
The pharmacokinetic interaction of enrofloxacin and trimethoprim was evaluated after single-dose intraperitoneal or oral co-administration in rats. Plasma concentrations of the two drugs were determined by high-performance liquid chromatography. Following intraperitoneal combination, a significant (P < 0.05) increase in mean values of plasma half-life (t 1/2) and maximum plasma concentration (C max) was observed for enrofloxacin and trimethoprim, respectively. There was a significant (P < 0.05) increase in mean values of area under the plasma drug concentration versus time from time zero to infinity (AUC0–∞) and C max between combined oral doses (10, 30 and 100 mg/kg) of both antibacterial drugs. Also, after oral conjugation a significant difference in mean values of MRT0–∞ was observed between lower (10 mg/kg) and higher (100 mg/kg) doses of both drugs. A significant increase in pharmacokinetic parameters of both drugs in combined intraperitoneal and oral doses indicated pharmacokinetic interaction of enrofloxacin and trimethoprim. Further study is recommended in other species of animals.
Similar content being viewed by others
References
Abo K, El Sooud, Al-Anati L (2011) Effect of flunixin on the disposition of enrofloxacin in calves. Insight Vet Res 1:1–4
Abu-Basha EA, Gehring R, Hantash TM, Al-Shunnaq AF, Idkaidek NM (2009) Pharmacokinetics and bioavailability of sulfadiazine and trimethoprim following intravenous, intramuscular and oral administration in ostriches. J Vet Pharmacol Ther 32:258–263
Anca M, Răpuntean GH, Oros NA, Cernea M (2007) Investigations on the synergic effects of aminoglycosides, polymyxins and fluoroquinolones combinations against pseudomonas aeruginosaisolated from dog. Lucrări ştiinłifice medicină veterinară 40:99
Anu R, Amit K, Ahmad AH, Malik JK (2007) Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep. Res Vet Sci 84:452–456
Atef M, Al-khayyat AA, Fahd K (2010) Pharmacokinetics and tissue distribution of trimethoprim in sheep. Transbound Emerg Dis 25:509–596
Batzias GC, Delis GA, Koutsoviti-Papadopoulou M (2005) Bioavailability and pharmacokinetics of sulfadiazine, N4-acetyl sulfadiazine and trimethoprim following intravenous and intramuscular administration of a sulfadiazine/trimethoprim combination in sheep. Vet Res Commun 29:699–712
Bermingham EC, Papich MG (2002) Pharmacokinetics after intravenous and oral administration of enrofloxacin in sheep. Am J Vet Res 63:1012–1017
Bista D, Palaian S, Shankar PR, Prabhu MM, Paudel R, Mishra P (2006) Understanding the essentials of drug interactions: a potential need for safe and effective use of drugs. KUMJ 4:421–430
Brooks MA, De Silva JAF, D’Arconte LM (1972) Determination of trimethoprim and its N-oxide metabolites in urine of man, dog, and rat by differential pulse polarography. J Pharm Sci 62:1395–1397
Choi MJ, Sileshi B, Lee SJ, Dereje D, Reza MA, Rhee MH, Kim TH, Park SCP (2012) The in vitro antibacterial activity of enrofloxacin–trimethoprim combination against five bacterial species. PVJ 32:363–366
Defeng Z, Aihua L, Jun X, Cheng J (2010) In vitro antibacterial effect of berberine hydrochloride and enrofloxacin to fish pathogenic bacteria. Aquac Res 41:1095–1100
Eliopoulos GM (1989) Synergism and antagonism. Infect Dis Clin North Am 3:399–406
Eliopoulos GM, Wennersten CB (1997) In vitro activity of trimethoprim alone compared with trimethoprim–sulfamethoxazole and other antimicrobials against bacterial species associated with upper respiratory tract infections. Diagn Microbiol Infect Dis 28:33–38
Elmas M, Tras B, Kaya S, Bas AL, Yazar E, Yarsan E (2001) Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats. Can J Vet Res 65:64–67
Eoin PQ, Joseph M, Donald GW, John S (2000) Mechanism of the antimicrobial drug trimethoprim revisited. FASEB J 14:2519–2524
Hooper CD (2001) Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32:9–15
Huovinen R, Wolfsont JS, Hooper DC (1992) Synergism of trimethoprim and ciprofloxacin In Vitro against clinical bacterial isolates. Eur J Clin Microbiol Infect Dis 11:255–257
Jaiprakash N, Nirbhay K, Jha HN, Jaya C (2009) Effect of probenecid on kinetics of enrofloxacin in lactating goats after Sc administration. Indian J Exp Biol 47:53–56
Lin JH, Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361–390
Ling–Ling Z, Jun-Ren Z, Kuan G, Hui J, Yan Z, Shan-Xiang J (2011) Effects of fluoroquinolones on CYP4501A and 3A in male broilers. Res Vet Sci 90:99–105
McKellar Q (1996) Clinical relevance of the pharmacologic properties of fluoroquinolones. Suppl Compend Contin Educ Pract Vet 18:14–20
Meret MF, Ju¨rgen B, Reinhard D, Ruth F, Gerd M, Ingeborg WS, Walter EH (2002) Dose-dependent increase of saquinavir bioavailability by the pharmaceutical aid cremophor EL. Br J Clin Pharmacol 53:576–581
Meshi T, Sato Y (1972) Studies on sulphamethoxazole/trimethoprim. Absorption, distribution, excretion, and metabolism of trimethoprim in rat. Chem Pharm Bull 20:2079–2090
Mikko N, Janne TB, Pertti JN (2004) Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76:239–249
Ogino T, Arai T (2007) Pharamcokinetic interactions of flunixin meglumine and enrofloxacin in ICR mice. Exp Anim 56:79–84
Post LO, Farrell DE, Cope CV, Baker JD, Myers MJ (2003) The effect of endotoxin and dexamethasone on enrofloxacin pharmacokinetic parameters in swine. J Pharmacol Exp Ther 304:889–895
Sanjib K, Chandana CB, Khanikar HN, Mohan P (2008) Kinetic studies of enrofloxacin after intravenous administration in yak. Pharmacol Online 3:545–551
Sharma PK, Ahmad AH, Sharma LD, Varma R (2003) Pharmacokinetics of enrofloxacin and the rate of formation of its metabolite ciprofloxacin following intravenous and intramuscular single dose administration to male buffalo calves. Vet J 166:101–104
Shyampada M, Nishith KP, Imran H, Chowdhury IH, Manisha D (2009) Antibacterial activity of ciprofloxacin and trimethoprim alone and in combination against Vibrio cholerae 01 biotype E1 Tor sero type Ogawa isolates. PJM 58:57–60
Tyczkowska K, Hedeen KM, Aucoin DP, Aronson AL (1989) High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue. J Chromatogr 493:337–346
Vancutsem PM, Babish JG, Schwark WS (1990) The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 80:173–186
Vandevenne M, Vandenbussche H, Verstraete A (2000) Detection time of drugs of abuse in urine. Acta Clin Belg 55:323–333
Wen X, Wang JS, Backman JT, Jouko L, Pertti JN (2002) Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9 respectively. Drug Metab Dispos 30:631–635
Wendy MB, Stephen HW (2002) The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 277:22491–22496
Acknowledgments
This research was supported in part by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2011-0021670), in part by the Next-Generation BioGreen 21 Program (No. PJ009007).
Conflict of interest
The authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
M.-J. Choi and B. Yohannes contributed equally.
Rights and permissions
About this article
Cite this article
Choi, MJ., Yohannes, S.B., Lee, SJ. et al. Pharmacokinetic interaction of enrofloxacin/trimethoprim combination following single-dose intraperitoneal and oral administration in rats. Eur J Drug Metab Pharmacokinet 39, 11–16 (2014). https://doi.org/10.1007/s13318-013-0142-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-013-0142-0